ArticleJournal of cutaneous and aesthetic surgery
Approach to a Patient with Cutaneous Malignancy in the Time of COVID-19 Pandemic.
Article in Journal of cutaneous and aesthetic surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- COVID-19 and Cutaneous Squamous Cell Carcinoma-Impact of the Pandemic on Unequal Access to Healthcare.Healthcare (Basel, Switzerland) · 2023Article
- Clinical Dermatology and COVID-19 Pandemic: Narrative Review.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is facing an unprecedented crisis of COVID-19 pandemic. This disease has weakened the economy, paralyzed the healthcare system, and worn out the human resources. Patients with cutaneous malignancy or skin cancer comprise a substantial part of the patient population and they need appropriate management of the cancer as they face the risk of COVID-19. In the wake of COVID-19 pandemic, the approach to management of cutaneous malignancy needs to be reassessed. The challenges in the management of skin cancer during COVID-19 are discussed in this article. Risk stratification considering the type and nature of malignancy, age, comorbidity, and treatment option is crucial in making the suggestions. Patient care, adequate infection control, safety of healthcare worker, and rational use of resources are the cruxes of management in this trying time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.